Semaglutide and terzipatide are glucagonlike peptide-1 (GLP-1) receptor agonists used for type 2 diabetes management. While both effectively control blood sugar, their impact on patient well-being may differ. This review explores patient satisfaction and quality of life (QoL) associated with semaglutide and terzipatide using patient-reported outcome measures (PROMs).
(2024). Comparing Semaglutide and Terzipatide: A Review of Patient Satisfaction and Quality of Life Outcomes in Type 2 Diabetes. Egyptian Society of Diabetes and Lipidology Journal, 4(1), -. doi: 10.21608/esdlj.2024.456232
MLA
. "Comparing Semaglutide and Terzipatide: A Review of Patient Satisfaction and Quality of Life Outcomes in Type 2 Diabetes", Egyptian Society of Diabetes and Lipidology Journal, 4, 1, 2024, -. doi: 10.21608/esdlj.2024.456232
HARVARD
(2024). 'Comparing Semaglutide and Terzipatide: A Review of Patient Satisfaction and Quality of Life Outcomes in Type 2 Diabetes', Egyptian Society of Diabetes and Lipidology Journal, 4(1), pp. -. doi: 10.21608/esdlj.2024.456232
VANCOUVER
Comparing Semaglutide and Terzipatide: A Review of Patient Satisfaction and Quality of Life Outcomes in Type 2 Diabetes. Egyptian Society of Diabetes and Lipidology Journal, 2024; 4(1): -. doi: 10.21608/esdlj.2024.456232
)
